<p class="doc-ti" id="d1e39-65-1" style="font-weight: 600; font-style: italic; text-align: center;">COMMISSION IMPLEMENTING DECISION (EU) 2017/1281</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">of 13 July 2017</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">authorising the placing on the market of L-ergothioneine as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;"> <span class="sp-normal"> <span class="italic">(notified under document C(2017) 4844)</span> </span> </p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">(Only the English text is authentic)</p><section><p class="normal">THE EUROPEAN COMMISSION,</p><p class="normal">Having regard to the Treaty on the Functioning of the European Union,</p><p class="normal">Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients, and in particular Article 7 thereof,</p><p class="normal">Whereas:</p><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(1)</p> </td> <td valign="top"> <p class="normal">On 25 July 2013, the company Tetrahedron made a request to the competent authorities of France to place synthetic L-ergothioneine (‘L-ergothioneine’) on the Union market as a novel food ingredient within the meaning of point (c) of Article 1(2) of Regulation (EC) No 258/97. The application excluded from the use infants, young children, pregnant and lactating women.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(2)</p> </td> <td valign="top"> <p class="normal">On 19 February 2015, the competent food assessment body of France issued its initial assessment report. In that report it came to the conclusion that L-ergothioneine meets the criteria for novel food ingredient set out in Article 3(1) of Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(3)</p> </td> <td valign="top"> <p class="normal">On 9 March 2015, the Commission forwarded the initial assessment report to the other Member States.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(4)</p> </td> <td valign="top"> <p class="normal">Reasoned objections were raised by other Member States within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(5)</p> </td> <td valign="top"> <p class="normal">On 14 October 2015, the Commission consulted the European Food Safety Authority (‘EFSA’) asking it to carry out an additional assessment for L-ergothioneine as novel food ingredient in accordance with Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(6)</p> </td> <td valign="top"> <p class="normal">On 26 October 2016, EFSA in its ‘Scientific Opinion on the safety of L-ergothioneine as a novel food pursuant to Regulation (EC) No 258/97’ concluded that L-ergothioneine is safe for the proposed uses and use levels.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(7)</p> </td> <td valign="top"> <p class="normal">That opinion gives sufficient grounds to establish that L-ergothioneine in the proposed uses and use levels complies with the criteria laid down in Article 3(1) of Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(8)</p> </td> <td valign="top"> <p class="normal">Directive 2002/46/EC of the European Parliament and of the Council lays down requirements on food supplements. The use of L-ergothioneine should be authorised without prejudice to the provisions of that Directive.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(9)</p> </td> <td valign="top"> <p class="normal">The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,</p> </td> </tr> </tbody> </table><p class="normal">HAS ADOPTED THIS DECISION:</p></section> <section><p class="ti-art" id="d1e176-65-1" style="font-style: italic; text-align: center;">Article 1</p><p class="normal">Without prejudice to Directive 2002/46/EC, L-ergothioneine as specified in Annex I may be placed on the Union market as a novel food ingredient to be used in food supplements intended for the general population, excluding infants and young children, and pregnant and lactating women, for the uses defined and at the maximum levels established in Annex II.</p></section> <section><p class="ti-art" id="d1e181-65-1" style="font-style: italic; text-align: center;">Article 2</p><p class="normal">The designation of L-ergothioneine authorised by this Decision on the labelling of the foodstuffs shall be ‘L-ergothioneine’.</p></section> <section><p class="ti-art" id="d1e190-65-1" style="font-style: italic; text-align: center;">Article 3</p><p class="normal">This Decision is addressed to Tetrahedron, 14, avenue de l'Opéra, 75001 Paris, France.</p></section>